The firm's $3.1M cash reserve appears insufficient to sustain its high-burn R&D model, likely necessitating external capital infusion within the next 12 to 18 months.
| Metric | Dec'24 | Dec'23 |
|---|
| Cash from Operations | -1.84M | -55.66K |
| Operating CF Margin % | -359.91% | -15.9% |
| Operating CF Growth % | -3200.25% | - |
| Net Income | -1.41M | 13.56K |
| Depreciation & Amortization | 104.73K | 2.45K |
| Stock-Based Compensation | 0 | 0 |
| Deferred Taxes | 26.58K | 4.09K |
| Other Non-Cash Items | 11.24K | 50.94K |
| Working Capital Changes | -567.81K | -126.7K |
| Change in Receivables | -11.02K | -63.86K |
| Change in Inventory | 28.52K | -30.57K |
| Change in Payables | 10.2K | 5.39K |
| Cash from Investing | -2.9M | -290 |
| Capital Expenditures | -74.91K | -290 |
| CapEx % of Revenue | 14.68% | 0.08% |
| Acquisitions | 0 | 0 |
| Investments | - | - |
| Other Investing | -2.84M | 0 |
| Cash from Financing | 7.73M | 113.89K |
| Debt Issued (Net) | -32.98K | -32.61K |
| Equity Issued (Net) | 1000K | 52.95K |
| Dividends Paid | 0 | 0 |
| Share Repurchases | 0 | 0 |
| Other Financing | -99.56K | 93.54K |
| Net Change in Cash | 3.05M | 56.96K |
| Free Cash Flow | -4.75M | -55.95K |
| FCF Margin % | -930.29% | -15.98% |
| FCF Growth % | -8386.27% | - |
| FCF per Share | - | - |
| FCF Conversion (FCF/Net Income) | 1.30x | -4.10x |
| Interest Paid | 772 | 2.14K |
| Taxes Paid | 0 | 0 |
Rapid Cash Runway Depletion
As indicated by the company's initial financial disclosures, YD Bio's cash flow trajectory remains deeply negative, with operating losses significantly outpacing the $510,360 in TTM revenue, suggesting that the firm is currently in a high-burn phase typical of early-stage biotechnology entities lacking commercial scale.
The absence of positive free cash flow is consistent with the company's -286.45% operating margin, reflecting heavy investment in R&D and laboratory infrastructure. Investors should monitor whether the current cash reserves of $3.1M can sustain operations until a major clinical milestone is achieved.
Based on the firm's reported operational structure, capital expenditures appear heavily weighted toward specialized laboratory equipment required for exosome isolation, which is essential for the company's diagnostic and regenerative pipeline development as noted in recent corporate filings.
This high capital intensity is a structural necessity for a firm attempting to standardize complex biological vesicles. The reliance on manual lab processes suggests that future cash flow will remain constrained until the company successfully transitions to automated, high-throughput diagnostic platforms.
According to the company's financial profile, capital deployment is currently focused exclusively on research and development, with no evidence of dividends or share repurchases, as the firm prioritizes the advancement of its exosome isolation protocols over near-term fiscal returns to shareholders.
The lack of debt on the balance sheet suggests a disciplined initial capital structure, yet the aggressive burn rate implies that future deployment will likely shift toward dilutive financing. Management's ability to allocate capital efficiently will be tested as the $3.1M cash reserve faces depletion.
As suggested by the company's February 2024 incorporation, the reported financial data may obscure the true extent of cash burn by potentially including non-recurring government grants or subsidies that do not reflect sustainable commercial product-market fit for its diagnostic kits.
The presence of warrants further complicates the cash flow outlook, as potential future exercises could alter the share count and capital structure significantly. Analysts should remain cautious regarding whether the reported revenue figures are truly representative of commercial traction or merely early-stage pilot program funding.
Quick answers to the most common questions about buying YDESW stock.
YD Bio Limited Warrants (YDESW) generated $-1.8M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
YD Bio Limited Warrants (YDESW) reported negative free cash flow of $4.7M in 2024, indicating capital requirements exceeded cash from operations.
YD Bio Limited Warrants (YDESW) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.